ANEMIA HEMOLÍTICA INDUZIDA POR MEDICAMENTO: UMA REVISÃO SISTEMÁTICA
DOI:
https://doi.org/10.47820/recima21.v3i12.2463Palavras-chave:
Anemia Hemolítica, Hemólise, MedicamentosResumo
A anemia hemolítica induzida por medicamentos (AHIM) é uma complicação rara, decorrente da interação de certas substâncias com a membrana dos eritrócitos, e que pode ser fatal se não elucidada rapidamente. A anemia pode ocorrer em resposta ao uso de qualquer terapia medicamentosa e muitas vezes é subdiagnosticada. Dessa maneira, o presente estudo tem como objetivo elaborar uma revisão sistemática da literatura sobre anemia hemolítica induzida por medicamentos nas bases de dados PubMed, Biblioteca Virtual em Saúde (BVS) e Periódicos Capes publicados nos últimos cinco anos. Ao longo do estudo foram selecionados 19 artigos científicos na presente revisão, dos quais 18 foram relatos de caso e 1 foi estudo retrospectivo. Observou-se que em apenas uma pesquisa o desfecho clínico decorrente da AHIM foi o óbito do paciente. Ao todo, a pesquisa revelou 19 princípios ativos relacionados com quadro de hemólise induzida por drogas.
Downloads
Referências
Al-Ansari RY, KHURAIM AA, Abdalla L, Hamid H, Zakary NY. Remsima (a Tumor Necrosis Factor (TNF)-α Inhibitor) induced hemolysis in a patient with Crohn's disease-Case report. Ann. Med. Surg. 2021;69(1):102768.
Mioti AGX, De Castro GFP. Alterações hematológicas induzidas por anti-inflamatórios não-esteroidais. Rev. Transformar. 2017;10(1):170-183
Mohammad S, Clowse MEB, Eudy AM, Criscione-Schreiber LG. Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6 PDH‐Deficient Patients. Arthritis Care Res; 2018;70(3):481-485.
Wu Y, Wu, Y, Yang Y, Chen B, Li J, Guo G, Xiong F. Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption. Frontiers in immunology. 2021;12:698541.
Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am J Health Syst Pharm. 2018;75(3):97-104,
Afra F, Mehri M, Namazi S. Bosentan-induced immune hemolytic anemia in 17 years old man. A case report. DARU Journal of Pharmaceutical Sciences. 2021; 29(1):211-215.
Agbuduwe C, Rugless M, Asba N, Proven M, Sivakumaran M. Severe drug-induced hemolysis in a patient with compound heterozygosity for Hb Peterborough (HBB: c. 334G> T) and Hb Lepore-Boston-Washington (NG_000007. 3: g. 63632_71046del). Hemoglobin, 2019;43(1): 56-59.
Gniadek TJ, Arndt PA, Leger RM, Zydowicz D, Cheng EY, Zantek ND. Drug‐induced immune hemolytic anemia associated with anti‐vancomycin complicated by a paraben antibody. Transfusion. 2018;58(1):181-188.
Quintanilla-Bordás C, Castro-Izaguirre E, Carcelén-Gadea M, Marín M. The first reported case of drug‐induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis. Transfusion. 2019;59(5):1648-1650.
Esteves A, Silva FT, Carvalho J, Carvoeiro A, Falgueiras P. Diclofenac-Induced Immune Hemolytic Anemia: A Case Report and Review of Literature. Cureus. 2021;13(1):e12903.
Gomez JC, Saleem T, Snyder S, Joseph M, Kanderi T. Drug-induced immune hemolytic anemia due to amoxicillin-clavulanate: a case report and review. Cureus. 2020;12(6):e8666.
Nguyen, TN, Maenulein E, Fihman V, Vinatier I, Moh Klaren J. Serologic characteristics of oxaliplatin antibodies in 15 patients with drug‐induced immune hemolytic anemia. Transfusion. 2021;61(5):1609-1616.
Wu S, Jing L, Feng Y, Chen L. Marked reduction in haemoglobin levels secondary to ceftizoxime-induced immune haemolytic anaemia in diabetic patients. J Clin Pharm Ther. 2020;45(4):812-814.
Dara RC, Sharma R, Bhardwaj H. Severe drug-induced immune hemolysis due to ceftriaxone. Asian J. Transfus. Sci. 2020;14(2)187-191.
Hamid NC, Malek KA, Nasir NM, Nasir NM. Pneumocystis jirovecii Pneumonia with a Normal Early Chest Radiography and Complicated with Drug-Induced Immune Hemolytic Anemia: A Case Report. The American Journal of Case Reports. 2022;23:e936278-1.
HIill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208-220.
Havey TC, Cserti-Gazdewich C, Sholzberg M, Keystone JS, Gold WL. Case report: recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin. Am J Trop Med. 2012;86(2):264-267.
Sanwal C, Kaldas A, Surani S, Bailey M. Rifampin-Induced Acute Intravascular Hemolysis Leading to Heme Pigment-Related Kidney Injury. Cureus. 2020;12(7):e9120.
Stevens-Cohen P, Zaghi F, Zhu L. A Rare Case of Hydrochlorothiazide-Induced Hemolytic Anemia. Cureus. 2021;13(8):e17453.
Johnson ST, Fueger JT, Gottschal JL. One center's experience: the serology and drugs associated with drug‐induced immune hemolytic anemia—a new paradigm. Transfusion. 2007;47(4):697-702, 2007.
BAE, Ju Young et al. Anemia hemolítica Coombs-negativa em um homem com COVID-19. Relatos de Casos Clínicos , v. 9, n. 7, pág. e04503, 2021.
Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30(2);66-79.
Gong JH, Liu GJ, Zhou F, Sun ZQ. Dabigatran-induced chronic progressive immune hemolytic anemia: A case report. J. Stroke Cerebrovasc. Dis. 2020;29(8):1-2.
Ishii H, Sato T, Ishibashi M, Yokoyama H, Saito T, Tasaki T, et al. A case of immune complex type hemolytic anemia by initial micafungin administration. Int J Infect Dis. 2022;0(0):755–757.
Wu Y, Wu Y, Ji Y, Liu Y, Wu D, Liang J, et al. Case Report: Oral Cimetidine Administration Causes Drug-Induced Immune Hemolytic Anemia by Eliciting the Production of Cimetidine-Dependent Antibodies and Drug-Independent Non-specific Antibodies. Front Med. 2021;8:1–9
Lois TAE, López-Polín A, Norman FF, Monge-Maillo B, López-Vélez, R, Perez-Molina JA. Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: Report on the experience of a referral centre for tropical infections in Spain. Travel medicine and infectious disease. 2017;15:52–56.
Fanello C, Onyamboko M, Lee SJ, Woodrow C, Setaphan S, Chotivanick K et al. Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine. BMC Infect. Dis. 2017;17(1):575-583.
Camprubí D, Pereira A, Rodriguez-Valero N, Almuedo A, Varo R, Calsas-Pascual C et al. Positive direct antiglobulin test in post-artesunate delayed haemolysis: more than a coincidence? Malar. J. 2019;18(1)128-135.
Savargaonkar D, Das MK, Verma A, Miltra JK, Yadav CP, Srivastava B. Delayed haemolysis after treatment with intravenous artesunate in patients with severe malaria in India. Malar J. 2020;19(1):39-45.
Lo YH, MOK K. L. High dose vitamin C induced methemoglobinemia and hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. Am J Emerg Med. 2020;38(11):2488.e3-2488.e5.
Maillart E, Leemans S, Van Noten H, Vandergraesen T, Mahadeb B, Salaouatchi MT et al. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. Infect Dis. 2020;52(9):659–61.
Downloads
Publicado
Edição
Seção
Categorias
Licença
Copyright (c) 2022 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
